Cytokinetics, Incorporated (NASDAQ:CYTK) Director Wendall Wierenga Sells 742 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Wendall Wierenga sold 742 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $48.61, for a total transaction of $36,068.62. Following the sale, the director now directly owns 24,559 shares of the company’s stock, valued at $1,193,812.99. The trade was a 2.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Wendall Wierenga also recently made the following trade(s):

• On Monday, October 28th, Wendall Wierenga sold 4,452 shares of Cytokinetics stock. The shares were sold at an average price of $52.25, for a total transaction of $232,617.00.

Cytokinetics Trading Up 0.8 %

CYTK stock opened at $49.02 on Tuesday. The company has a market capitalization of $5.79 billion, a price-to-earnings ratio of -9.11 and a beta of 0.80. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a 1-year low of $32.70 and a 1-year high of $110.25. The business has a 50 day simple moving average of $52.51 and a two-hundred day simple moving average of $54.09.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $1.21 million. The business’s revenue was up 22.5% compared to the same quarter last year. During the same period last year, the company posted ($1.35) EPS. Research analysts anticipate that Cytokinetics, Incorporated will post -5.25 EPS for the current fiscal year.

Analyst Ratings Changes

CYTK has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research note on Friday, October 18th. Mizuho lifted their target price on Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. boosted their price target on Cytokinetics from $65.00 to $71.00 and gave the company an “overweight” rating in a report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research note on Wednesday, September 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $83.93.

Institutional Investors Weigh In On Cytokinetics

Large investors have recently made changes to their positions in the company. Darwin Global Management Ltd. bought a new position in Cytokinetics during the second quarter valued at approximately $246,074,000. Geode Capital Management LLC boosted its position in shares of Cytokinetics by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,848,584 shares of the biopharmaceutical company’s stock valued at $150,433,000 after acquiring an additional 109,938 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Cytokinetics by 42.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company’s stock valued at $69,769,000 after purchasing an additional 395,709 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Cytokinetics by 38.9% in the third quarter. Westfield Capital Management Co. LP now owns 1,212,886 shares of the biopharmaceutical company’s stock worth $64,040,000 after purchasing an additional 339,373 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in Cytokinetics by 17.2% during the third quarter. Janus Henderson Group PLC now owns 1,143,830 shares of the biopharmaceutical company’s stock valued at $60,399,000 after purchasing an additional 167,501 shares in the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.